Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

Nuvation Bio (NYSE:NUVB) released its quarterly earnings results on Thursday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04), FiscalAI reports. The firm had revenue of $31.69 million for the quarter, compared to analysts’ expectations of $27.03 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
• Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
• Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
• The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
• Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Price Performance

NUVB traded down $0.28 during trading on Thursday, reaching $6.09. The stock had a trading volume of 8,391,554 shares, compared to its average volume of 6,039,828. The business has a 50-day moving average of $5.72 and a 200-day moving average of $5.23. Nuvation Bio has a one year low of $2.18 and a one year high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44. The stock has a market cap of $2.12 billion, a PE ratio of -14.16 and a beta of 1.52.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright lifted their price objective on Nuvation Bio from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Royal Bank Of Canada restated an “outperform” rating on shares of Nuvation Bio in a research note on Wednesday, July 22nd. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Finally, Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.88.

Insider Transactions at Nuvation Bio

In related news, insider Stacy Markel sold 125,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total transaction of $753,750.00. Following the transaction, the insider directly owned 32,591 shares of the company’s stock, valued at approximately $196,523.73. This trade represents a 79.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 63,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the sale, the insider owned 53,000 shares of the company’s stock, valued at $319,060. The trade was a 54.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 235,668 shares of company stock worth $1,419,495. 30.11% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Nuvation Bio by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company’s stock valued at $191,000 after purchasing an additional 4,608 shares in the last quarter. Millennium Management LLC raised its position in Nuvation Bio by 52.4% in the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after purchasing an additional 1,298,131 shares during the period. Envestnet Asset Management Inc. bought a new stake in Nuvation Bio in the second quarter worth $92,000. Creative Planning lifted its stake in Nuvation Bio by 267.1% in the second quarter. Creative Planning now owns 39,288 shares of the company’s stock worth $77,000 after purchasing an additional 28,585 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new stake in Nuvation Bio during the second quarter valued at about $29,000. 61.67% of the stock is owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.